Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practicing in specific cardiology domains.
Dr. Jan Steffel,
As expected, there were hardly any seats left in the session “New oral anticoagulants / clinical challenges” due to the timeliness of the topic and the list of high ranking speakers. Chaired by Dr. Steffel (Zurich, Switzerland) and Dr. Andreotti (Rome/Italy), Dr. Ottani (Piangipane/Italy) started off the session by explaining the necessity of, and summarizing the modalities for bleeding risk stratification.
Dr. Svensson from Malmo (Sweden) continued on the possibilities of monitoring new oral anticoagulants (NOACs) with a specific emphasis on situations in which it makes sense to do so – and when not. Using 4 patient case scenarios, Dr. Halvorsen (Oslo, Norway) explained the management of patients undergoing percutaneous coronary interventions or electrophysiological testing, with a special note on peri-interventional anticoagulation regimens and the necessity for triple anticoagulation. Finally, Dr. Verheugt from Amsterdam (Netherlands) explained management issues in patients undergoing major and/or urgent surgical procedures, thereby also touching on the possibilities as well as limitations and risks of antagonizing anticoagulation therapy (both vitamin K antagonists as well as NOACs).
Lively discussion amongst the audience, chairpersons and speakers reflected both the high interest in these novel substances, and the desire to use them correctly – even in tricky situations – to maximize patient benefit.
New oral anticoagulants - clinical challenges
Our mission: To reduce the burden of cardiovascular disease
© 2017 European Society of Cardiology. All rights reserved